Virtual Library

Start Your Search

Paula Mendoça Batista



Author of

  • +

    P2.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 187)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.16-14 - Survival Rates in Non-Small Cell Lung Cancer Patients in the Brazilian Private Health System: A Cohort Study (ID 2328)

      10:15 - 18:15  |  Author(s): Paula Mendoça Batista

      • Abstract

      Background

      Lung cancer is the leading cause of cancer-related mortality in Brazil. Non-small cell lung cancer (NSCLC) is the most prevalent subtype and is associated with high rates of mortality. Despite being diagnosed in late phases, few studies have addressed the survival rates of such disease in the Brazilian private health system.

      Method

      An exploratory cohort study based on administrative database claims that included patients with advanced NSCLC diagnosed between 2011 to 2016. The inclusion criteria were defined as having lung cancer diagnosis (ICD-10 code 34 with stage III and IV) and compatible histologic subtype for NSCLC, such as adenocarcinoma, squamous cell, non-squamous cell and others. Non-parametric statistics (Kaplan Meier method, product limit estimator) was used to perform survival analyses, considering diagnosis as index date.

      Result

      A total of 5,016 patients were included in this study. At time of diagnosis, most patients had stage IV disease (67%) and were 60 to 69 years old (33.7%). Patients took 31 days on average to receive diagnosis after being attended by a health service. The clinical oncologist was the first professional to attend the patient in 44% of cases. The average time to start the treatment was 35 days and where patients received chemotherapy (32%) or chemotherapy plus radiotherapy (21%). The median survival rate for stage III NSCLC was 11 months; while for stage IV, 50% of the population was alive in 6.5 months.

      Conclusion

      This study suggests a high percentage of patients diagnosed with stage IV disease. The survival rates were very low, comparable to the public healthcare system where the patient doesn’t have access to all medications approved by ANVISA, Brazilian Regulatory Agency, (median overall survival of 8 to 12 months). The results show an opportunity to improve care in private healthcare system.